ライフサイエンスコーパス: platelet adhesion

1 s show normal bleeding times despite reduced platelet adhesion.

2 ne cytoskeleton and for the stabilization of platelet adhesion.

3 f LIMK1(-/-) platelets in VWF-induced stable platelet adhesion.

4 exposure on endothelial cells and augmented platelet adhesion.

5 nd thrombosis, in part, by supporting stable platelet adhesion.

6 ing events are crucial for the initiation of platelet adhesion.

7 e the ability to significantly reduce static platelet adhesion.

8 elet aggregation and beta1 integrin-mediated platelet adhesion.

9 a receptor other than GPIbalpha can mediate platelet adhesion.

10 lted in the loss of alpha(IIb)beta3-mediated platelet adhesion.

11 ed von Willebrand factor (VWF) and secondary platelet adhesion.

12 hat could serve as a driving force for tight platelet adhesion.

13 nt ligand resulted in a greater stability in platelet adhesion.

14 role of circulating VWF in the initiation of platelet adhesion.

15 VWF multimers that, as a result, can mediate platelet adhesion.

16 < .05 vs wild-type), but not in the initial platelet adhesion.

17 -coated substrates to examine flow-dependent platelet adhesion.

18 lusters, even in the absence of any platelet-platelet adhesion.

19 von Willebrand factor multimers could reduce platelet adhesion.

20 d to quantify endothelial-associated VWF and platelet adhesion.

21 as observed using fluorescence imaging, and platelet adhesion (81.7 +/- 2.5%) in vitro over a 2 h pe

22 uced protein absorption (64.7% decrease) and platelet adhesion (85.6% decrease) compared to bare PCL

23 ng cleavage by ADAMTS13, may promote initial platelet adhesion above glomerular endothelial cells.

24 transmitted cellular forces are critical for platelet adhesion, activation, aggregation and contracti

25 Platelet adhesion, activation, and aggregation at sites

26 The role of platelet adhesion, activation, and aggregation in acute

27 multimeric plasma glycoprotein that mediates platelet adhesion, activation, and aggregation.

28 NETs perfused with blood caused platelet adhesion, activation, and aggregation.

29 involved in several key steps of thrombosis: platelet adhesion/activation, thrombus growth, and stabi

30 a1 in their alpha-granules and release it on platelet adhesion/activation.

31 the relationship between RBC hematocrit and platelet adhesion activity.

32 VWF and ADAMTS13 are major determinants of platelet adhesion after vessel injury.

33 CXCL16-induced stimulation of platelet adhesion again was prevented by phosphatidylino

34 ereby regulates diverse functions, including platelet adhesion, aggregation, and procoagulant activit

35 nteracts with CLEC-2 on platelets, mediating platelet adhesion, aggregation, and secretion to guide t

36 cidating the molecular mechanisms leading to platelet adhesion, aggregation, shape change, and secret

37 lation in a dose-dependent manner as well as platelet adhesion, although total plaque area was reduce

38 the TKI ponatinib that involves VWF-mediated platelet adhesion and a secondary microvascular angiopat

39 nin-211 (alpha2beta1gamma1), allow efficient platelet adhesion and activation across a wide range of

40 Whether vascular laminins support platelet adhesion and activation and the significance of

41 In this, platelet adhesion and activation leads to the formation

42 t aggregation and activation studies reduced platelet adhesion and activation partially.

43 eatment with MMP inhibitors partly prevented platelet adhesion and activation, as well as vWF express

44 coating prevents fibrin attachment, reduces platelet adhesion and activation, suppresses biofilm for

45 , functions during blood clotting to promote platelet adhesion and activation.

46 tor (VWF), glycoprotein (GP) Ib-IX, mediates platelet adhesion and activation.

47 ), glycoprotein (GP) Ib-IX, mediates initial platelet adhesion and activation.

48 ycoprotein Ib-IX (GPIb-IX), mediates initial platelet adhesion and activation.

49 nded periods of time (> 20 h) while reducing platelet adhesion and activation.

50 with integrin alpha(2)beta(1) are vital for platelet adhesion and activation; however, how these int

51 roles of alpha2beta1 and GPVI in supporting platelet adhesion and aggregate formation on collagen at

52 m the basis of a unifying two-state model of platelet adhesion and aggregate formation on collagen th

53 is a plasma metalloproteinase that regulates platelet adhesion and aggregation by cleaving ultra-larg

54 Integrins are critical for platelet adhesion and aggregation during arterial thromb

55 lular matrices (ECMs) that are essential for platelet adhesion and aggregation during hemo stasis and

56 Platelet adhesion and aggregation enable a haemostatic p

57 and unbinding that underlie the dynamics of platelet adhesion and aggregation in blood flow.

58 Recombinant ADAMTS13 reduced platelet adhesion and aggregation in histamine-activated

59 Platelet adhesion and aggregation play a critical role i

60 onary syndromes aim toward limiting platelet-platelet adhesion and aggregation processes.

61 Platelet adhesion and aggregation to the angioplasty sit

62 In spite of these functional defects, platelet adhesion and aggregation were better supported

63 However, platelet adhesion and aggregation were reduced in vitro

64 ves von Willebrand factor multimers, reduces platelet adhesion and aggregation, and downregulates thr

65 fields that have revealed new mechanisms of platelet adhesion and aggregation.

66 derlying the dynamics of fibrinogen-mediated platelet adhesion and aggregation.

67 rand's factor receptor complex that mediates platelet adhesion and aggregation.

68 sis and thrombosis because they mediate both platelet adhesion and aggregation.

69 r signaling events that contribute to stable platelet adhesion and aggregation.

70 selectin, which induce leukocyte rolling and platelet adhesion and aggregation.

71 lfatides as a major ligand for P-selectin in platelet adhesion and aggregation.

72 e in physiological processes associated with platelet adhesion and aggregation.

73 (3) is the fibrinogen receptor that mediates platelet adhesion and aggregation.

74 t with an inhibitory role for supervillin in platelet adhesion and arterial thrombosis.

75 (Fn1(syn/syn)) suffer from surprisingly mild platelet adhesion and bleeding defects due to delayed th

76 binding site for alpha(IIb)beta3 involved in platelet adhesion and clot retraction and define the new

77 eptides duplicating these segments inhibited platelet adhesion and clot retraction but not platelet a

78 jury site is a complex process that involves platelet adhesion and clot stiffening/contraction in the

79 Combined blockade of leukocyte/platelet adhesion and coagulation may provide convincing

80 odies recognize PF4-VWF complexes, promoting platelet adhesion and enlargement of thrombi within the

81 we show that the physical interplay between platelet adhesion and hemodynamics in a microchannel man

82 nd factor (VWF) to GP Ib-IX mediates initial platelet adhesion and increases the subsequent adhesive

83 ptor, glycoprotein Ib-IX (GPIb-IX), mediates platelet adhesion and induces signaling leading to integ

84 ycoprotein Ibalpha (GPIbalpha) promotes both platelet adhesion and inflammatory actions of platelets

85 Platelet cargo, platelet adhesion and platelet activation but not platel

86 le in hemostasis and thrombosis by mediating platelet adhesion and platelet aggregation.

87 nteractions with P-selectin are important in platelet adhesion and platelet aggregation.

88 c binding site for alphaIIbbeta3 involved in platelet adhesion and platelet-mediated fibrin clot retr

89 ge, and surface area expansion to facilitate platelet adhesion and plug formation.

90 X-V complex within rafts is crucial for both platelet adhesion and postadhesion signaling.

91 decipher mechanisms of A1-GPIbalpha-mediated platelet adhesion and resolve dynamic secondary structur

92 show that, in fact, both PS and PE influence platelet adhesion and secretion.

93 nd shear microfluidic assays, Slit2 impaired platelet adhesion and spreading on diverse extracellular

94 ted the ILK-PINCH-Parvin complex and altered platelet adhesion and spreading.

95 asing substrate stiffness leads to increased platelet adhesion and spreading.

96 Unexpectedly, free Hb also promoted firm platelet adhesion and stable microthrombi on VWF.

97 n (nominal values) tensions generated during platelet adhesion and tensions above 54 piconewton gener

98 d by their ability to support flow-dependent platelet adhesion and their ability to inhibit ristoceti

99 endothelial collagen acts as a substrate for platelet adhesion and thrombus formation after vascular

100 High shear force critically regulates platelet adhesion and thrombus formation during ischemic

101 that vWF plays a critical role in mediating platelet adhesion and thrombus formation following mesen

102 ne deficiency significantly accelerates both platelet adhesion and thrombus formation in mice followi

103 von Willebrand factor (vWF) mediates platelet adhesion and thrombus formation via its interac

104 wed that nanofibrous scaffolds alone induced platelet adhesion and thrombus formation, which was supp

105 articularly collagen, play a pivotal role in platelet adhesion and thrombus formation.

106 of integrin alphaIIbbeta3 to support stable platelet adhesion and thrombus formation.

107 ), glycoprotein (GP) Ib-IX, mediates initial platelet adhesion and transmits signals leading to plate

108 Furthermore, P3 supported platelet adhesion and was an effective inhibitor of plat

109 kindlin-3 was introduced into HEL cells and platelets; adhesion and spreading of both cell types wer

110 ltimers adhere to endothelial cells, support platelet adhesion, and may induce microvascular thrombos

111 Free Hb (>/=50 mg/dL) effectively augmented platelet adhesion, and microthrombi formation on fibrin(

112 sion of the platelet receptor vWF, increased platelet adhesion, and platelet activation.

113 vities, including factor XIIIa crosslinking, platelet adhesion, and platelet-mediated clot retraction

114 ity, inflammatory response, B-cell response, platelet adhesion, and T-helper lymphocyte activity.

115 PS was enriched dramatically and decreased platelet adhesion as well as secretion from delta-, alph

116 ks VWFpp binding to VWF-D'D3, also abrogated platelet adhesion, as shown by shear-induced platelet ag

117 recombinant VWFpp in both flow-chamber-based platelet adhesion assays and viscometer-based shear-indu

118 Versican facilitates platelet adhesion at low shear and cooperates with colla

119 e in hemostasis and thrombosis by initiating platelet adhesion at sites of arterial injury through in

120 Platelet adhesion at sites of vascular injury is mediate

121 (VWF) is a multimeric protein that mediates platelet adhesion at sites of vascular injury, and ADAMT

122 d from vascular endothelial cells, initiates platelet adhesion at sites of vascular injury.

123 echanism, ADAMTS13 activity might compromise platelet adhesion at sites of vascular injury.

124 -selectin expression, VCAM-1 expression, and platelet adhesion between 30 and 40 weeks of age.

125 coprotein Ib-IX-V complex, not only mediates platelet adhesion but also transmits signals leading to

126 nce of endothelial cells in stenoses reduces platelet adhesion but increases sickle cell disease (SCD

127 -111 (alpha1beta1gamma1) is known to support platelet adhesion but is absent from most blood vessels,

128 tirofiban (anti-GPIIb/IIIa) did not prevent platelet adhesion but nearly eliminated the deposition o

129 deficiency of pFN did not affect the initial platelet adhesion, but a delay of several minutes in thr

130 is a multidomain metalloprotease that limits platelet adhesion by a feedback mechanism in which fluid

131 gands may promote the feedback inhibition of platelet adhesion by stimulating the cleavage of domain

132 tween the thrombin and collagen receptors in platelet adhesion by utilizing a collagen-related peptid

133 Too little platelet adhesion causes bleeding that is typical of von

134 tigate the effect of a drug known to inhibit platelet adhesion (clopidogrel) and, in the presence of

135 cant reductions in I/R-induced leukocyte and platelet adhesion compared with wild-type mice exposed t

136 M: 146.2 +/- 20.4 min, p < 0.05) and reduced platelet adhesion, complement activation, coagulation ac

137 brinogen binding to alpha(IIb)beta(3) during platelet adhesion decreased integrin-associated PP2A act

138 balpha) and genetically engineered mice with platelet adhesion defects, we investigated the role of p

139 daptor absent in patients with leukocyte and platelet adhesion deficiency syndrome and is critical fo

140 y of von Willebrand factor (VWF) to initiate platelet adhesion depends on the number of monomers in i

141 F in plasma of patients with ALI/ALF support platelet adhesion, despite a relative loss of function o

142 ogrel) and, in the presence of the drug, the platelet adhesion due to activation by 5.00 microM ADP d

143 in long string-like structures that initiate platelet adhesion during hemostasis and thrombosis.

144 intracellular binding partners, anchors the platelet adhesion glycoprotein (GP) Ib-IX-V receptor to

145 t glycoprotein Ibalpha that supports initial platelet adhesion in absence of von Willebrand factor (V

146 estigate the role of each external factor on platelet adhesion in an in vitro setting.

147 iolar vasodilation and venular leukocyte and platelet adhesion in mice after injection with either mo

148 uggesting that TSP1 does not mediate initial platelet adhesion in the absence of VWF.

149 This work revealed: (1) a priming role of platelet adhesion in thrombus contraction and subsequent

150 -induced thrombosis model, we report similar platelet adhesion in Tsp1(-/-)/Vwf(-/-) mice compared wi

151 A NPs have also proven capable of inhibiting platelet adhesion in vitro with a reduced IC50 of 1.83 +

152 In addition, MSCs, as ECs, resisted platelet adhesion in vitro, which depended on cell-surfa

153 in a ristocetin cofactor ELISA and increased platelet adhesion in whole blood to collagen under arter

154 fundamental relationship of the dynamics of platelet adhesion, including these interrelating factors

155 ha(IIb)beta(3) by immobilized ligands during platelet adhesion induces a transmembrane conformation c

156 Platelet adhesion is an essential function in response t

157 The enhanced alpha(2)beta(1)-mediated platelet adhesion is controlled by phospholipase C (PLC)

158 cal importance of rapid bond dissociation in platelet adhesion is demonstrated by kinetic characteriz

159 Thus, GPIb-IX-dependent platelet adhesion is doubly controlled by vWF conformati

160 The process of platelet adhesion is initiated by glycoprotein (GP)Ib an

161 cally in a number of settings such as during platelet adhesion, leukocyte trans-migration, and angiog

162 of von Willebrand disease, whereas too much platelet adhesion may cause thrombotic thrombocytopenic

163 Ibalpha, thrombin could potentially act as a platelet adhesion molecule or receptor dimerisation trig

164 To examine the role of the platelet adhesion molecule von Willebrand factor (vWf) i

165 f platelets with blocking antibodies against platelet adhesion molecules did not alter their effect o

166 focused solely on recapitulating aspects of platelet adhesion; more complex platelet behaviours such

167 pite the presence of arterial shear, delayed platelet adhesion occurred and stable thrombi formed.

168 a is not critical for integrin activation or platelet adhesion on collagen.

169 istent with the known lack of shear-enhanced platelet adhesion on fibrinogen-coated surfaces.

170 on by NO of alphaIIb/beta3 integrin-mediated platelet adhesion on immobilized fibrinogen, mediated in

171 ibited platelet aggregation while preserving platelet adhesion on plaque.

172 Although the biology of platelet adhesion on subendothelial matrix after vascula

173 or glycoprotein VI and strongly affects firm platelet adhesion on von Willebrand factor (VWF) under a

174 ew NO-release coating exhibit no significant platelet adhesion or thrombus formation, but control sen

175 ferences were found in either initial single-platelet adhesion or thrombus volume.

176 Platelet adhesion (P<0.01) and activation (P=0.03) on PV

177 rospot-based technique, in which we assessed platelet adhesion, platelet activation, thrombus structu

178 shared with those elicited by the inhibitory platelet adhesion receptor PECAM-1 (platelet endothelial

179 Moreover, targeting another platelet adhesion receptor, glycoprotein IIb/IIIa (GPIIb

180 ty due to molecular abnormalities in a major platelet adhesion receptor, integrin alphaIIbbeta3.

181 The platelet adhesion receptor, the glycoprotein Ib-IX-V com

182 dhesion defects, we investigated the role of platelet adhesion receptors in stabilizing tumor vessels

183 r injury in that it does not depend on major platelet adhesion receptors or GPCR signaling.

184 in genetically engineered mice lacking major platelet adhesion receptors or their activators (alphaII

185 into thrombi is mediated by interactions of platelet adhesion receptors with ligands on the injured

186 ntibody M3/38) or collagen receptor-mediated platelet adhesion (revacept, a dimeric platelet collagen

187 f the immunoglobulin superfamily involved in platelet adhesion, secretion and aggregation.

188 sduce those cues into differential levels of platelet adhesion, spreading, and activation provides bi

189 tivity mediate substrate stiffness-dependent platelet adhesion, spreading, and activation to differen

190 15N-1H NMR and platelet adhesion studies show that the peptide heterotr

191 shear stress conditions effectively blocked platelet adhesion, suggesting that the initial interacti

192 In vitro platelet adhesion tests indicate that the xerogel coatin

193 The second is an F11R-mediated platelet adhesion that is not dependent on either the Fc

194 to lowering lipids, statins favorably affect platelet adhesion, thrombosis, endothelial function, inf

195 injury, von Willebrand factor (VWF) mediates platelet adhesion through binding to platelet glycoprote

196 A molecule identified as critical for platelet adhesion to a cytokine-inflamed endothelial sur

197 ing high-affinity GPIbalpha binding and firm platelet adhesion to a partially disordered A1 domain.

198 mechanism for the regulation of rheological platelet adhesion to A1 based on cooperative flexibility

199 We demonstrate that platelet adhesion to alpha2-CRP is substantially enhance

200 -coupled receptors (GPCRs) produces enhanced platelet adhesion to alpha2-CRP.

201 al microscopy revealed a >3-fold increase in platelet adhesion to angiogenic vessels of Matrigel comp

202 alpha may alter the mechanical regulation of platelet adhesion to cause hemostatic defects as found i

203 m-Fab-F inhibits both GPVI-dependent static platelet adhesion to collagen and thrombus formation on

204 tivation were confirmed in vitro by studying platelet adhesion to collagen in flow conditions, integr

205 ficient beta1 integrin show strongly reduced platelet adhesion to collagen in vitro and in a carotis

206 GxO/SGER peptides inhibited platelet adhesion to collagen monomers with order of pot

207 egrin alpha2beta1 play significant roles for platelet adhesion to collagen under flow and that the lo

208 nder static conditions and completely blocks platelet adhesion to collagen under flow conditions at h

209 genetic approaches to study human and mouse platelet adhesion to collagen under flow conditions.

210 elet activation, a requirement for efficient platelet adhesion to collagen under flow.

211 eceptor density results in severe defects in platelet adhesion to collagen under flow.

212 activation of T cells (LAT) is critical for platelet adhesion to collagen under flow.

213 Platelet adhesion to collagen via collagen receptors is

214 2 beta 1 integrin is a critical mediator of platelet adhesion to collagen within the vessel wall aft

215 ptor, glycoprotein VI (GPVI) and its role in platelet adhesion to collagens.

216 orted that mouse, as well as human GPVI, had platelet adhesion to colon and breast cancer cells.

217 In contrast, thrombin-stimulated platelet adhesion to cultured human umbilical vein endot

218 Platelet adhesion to dA1VWF induced Src kinase-dependent

219 ace-bound von Willebrand factor and supports platelet adhesion to damaged vascular surfaces.

220 ha) to von Willebrand factor (VWF) initiates platelet adhesion to disrupted vascular surface under ar

221 CXCL16 enhanced platelet adhesion to endothelium in vitro after high art

222 , we found that ADAMTS13 down-regulates both platelet adhesion to exposed subendothelium and thrombus

223 Platelet adhesion to ferric chloride-treated mesenteric

224 This Fab also reduced platelet adhesion to fibrin at low (300 s(-1)) and high

225 we studied the effect of hemoglobin (Hb) on platelet adhesion to fibrin(ogen) under conditions of di

226 both alphav beta3 and alphaIIb beta3 mediate platelet adhesion to fibrin.

227 demonstrate this technique by measurement of platelet adhesion to fibrinogen as a means to quantify t

228 Platelet adhesion to fibrinogen caused a rapid increase

229 t adhesion and was an effective inhibitor of platelet adhesion to fibrinogen fragments.

230 Moreover, platelet adhesion to fibrinogen stimulates actin rearran

231 trated that alphaIIb beta3 integrin mediates platelet adhesion to fibrinogen, whereas both alphav bet

232 Platelet adhesion to hepatic sinusoidal endothelial cell

233 nstrated GPR56 and shear-force dependence of platelet adhesion to immobilized collagen.

234 Upon platelet adhesion to immobilized Fg, CIB localizes to th

235 , Y731 and Y774 undergo phosphorylation upon platelet adhesion to immobilized fibrinogen, which was i

236 e-rich repeat (LRR) protein family, mediates platelet adhesion to immobilized von Willebrand factor (

237 in the function of endothelial cells and in platelet adhesion to inflamed endothelium.

238 ) with von Willebrand factor (VWF) initiates platelet adhesion to injured vascular wall to stop bleed

239 Ibalpha and von Willebrand factor initiates platelet adhesion to injured vessel walls, and the adhes

240 e blood von Willebrand factor (VWF) mediates platelet adhesion to injured vessels by sequestering pla

241 (GPIbalpha) binding to vWF, which initiates platelet adhesion to injured vessels.

242 APC prior to induction of NETosis inhibited platelet adhesion to NETs.

243 intravascular inflammatory events, including platelet adhesion to neutrophils, an important event in

244 mediated adhesion, L-selectin expression, or platelet adhesion to neutrophils, suggesting that cytosk

245 Furthermore, they indicate that platelet adhesion to osteopontin-coated surfaces require

246 and elicited anti-pig antibodies, recipient platelet adhesion to pig hematopietic progenitor cells,

247 Src family and Syk tyrosine kinases promotes platelet adhesion to primary mouse lymphatic endothelial

248 phenotypical range of bleeding from lack of platelet adhesion to severe thrombocytopenia.

249 is a multimeric plasma protein that mediates platelet adhesion to sites of vascular injury.

250 VWF is required for platelet adhesion to sites of vessel injury, a process v

251 In addition, aegyptin attenuates platelet adhesion to soluble or fibrillar collagen.

252 e show that in ferric chloride-injured veins platelet adhesion to subendothelium is decreased and thr

253 1 EMI domain (GST-EMI) competitively reduced platelet adhesion to surface-coated PEAR1, diminished pl

254 To determine whether platelet adhesion to surfaces coated with the matrix pro

255 gs support the hypothesis that inhibition of platelet adhesion to the brain microvasculature protects

256 oprotein ligand 1 axis, followed by (2) firm platelet adhesion to the endothelium via interaction of

257 e (NO) production, a recognized inhibitor of platelet adhesion to the endothelium, increased the numb

258 optimization studies, and studies involving platelet adhesion to the immobilized endothelium, were p

259 Weibel-Palade bodies (WPBs) is required for platelet adhesion to the injured vessel wall.

260 Cs to participate in thrombosis by mediating platelet adhesion to the intact endothelial surface.

261 were implicated in recognition of P3, since platelet adhesion to the peptide was blocked by function

262 Platelet adhesion to the PF4-VWF-HIT antibody complexes

263 efined incubation time quantitatively assays platelet adhesion to the protein matrix.

264 monstrating the role of P2Y(12) in mediating platelet adhesion to thrombogenic surfaces (collagen, vo

265 In this respect, therefore, platelet adhesion to vascular wall structures, to one an

266 Platelet adhesion to von Willebrand factor (VWF) activat

267 complex plays a critical role in initiating platelet adhesion to von Willebrand factor (vWF) at the

268 ural integrity to the plasma membrane during platelet adhesion to von Willebrand factor (VWF) under h

269 bocytopenia, shedding of GPIbalpha, impaired platelet adhesion to von Willebrand factor, and inabilit

270 mutation, Gly233Val, promotes and stabilizes platelet adhesion to VWF at shear rates that do not supp

271 Platelet adhesion to VWF fibers was reduced in proportio

272 The A1 domain, responsible for platelet adhesion to VWF in hemostasis, unfolds through

273 2 modulators, ristocetin and botrocetin, and platelet adhesion to VWF surfaces under flow.

274 kout platelets were also defective in stable platelet adhesion to VWF under shear stress that is inde

275 Platelet adhesion to vWF was impaired in P2Y12-/- platel

276 tes of A1 takes precedence and drives normal platelet adhesion to VWF.

277 Platelet adhesion to wild-type (WT) A1A2A3 protein, coll

278 itative formulas describing how the rates of platelet adhesion, translocation, and detachment are def

279 ucidate the mechanism of thrombus growth and platelet adhesion under conditions of arterial shear rat

280 ed VWF binding to platelets and VWF-mediated platelet adhesion under flow conditions.

281 examine the role of integrin alphavbeta3 in platelet adhesion under flow in structurally intact cere

282 licular system) that results in dysregulated platelet adhesion under haemodynamic shear stress.

283 latelet activation as well as CXCL16-induced platelet adhesion under high arterial shear stress in vi

284 be that platelet vimentin engages VWF during platelet adhesion under high shear stress.

285 ns that differentially alter the strength of platelet adhesion under shear flow.

286 sis, second-messenger production, and stable platelet adhesion under shear in vivo.

287 In both cases, we find that the rate of platelet adhesion varies greatly with the RBC hematocrit

288 ing stimulation with cytokines and following platelet adhesion via P-selectin.

289 or PI3KC2alpha in regulating shear-dependent platelet adhesion via regulation of membrane structure,

290 Besides promoting platelet adhesion, VWF carries Factor VIII.

291 nhibition and 5.00 microM ADP, the affect on platelet adhesion was further increased to 127 +/- 5.2.

292 I [CalDAG-GEFI]), thus indicating that firm platelet adhesion was not necessary for their supporting

293 RBC-platelet adhesion was reduced in half by antibodies agai

294 ar signal for endothelial-associated VWF and platelet adhesion were five- to sixfold higher in ponati

295 heir inhibitory effects on GPIb-IX-dependent platelet adhesion were reversed by exogenous cGMP.

296 hrough GPIbalpha are involved in maintaining platelet adhesion when external forces are absent.

297 sclerosis reduces endothelial activation and platelet adhesion, which are likely responsible for the

298 o the surface of biomaterial correlates with platelet adhesion, which is mediated by von Willebrand f

299 endorepellin supported alpha2beta1-dependent platelet adhesion, without appreciably activating or agg

300 be both collagen responders and mediators of platelet adhesion, yet the signaling kinetics emanating